The webinar will feature a fireside chat with Key Opinion Leaders (KOLs) Rohit Loomba, MD, MHSc (University of California at San Diego School of Medicine), Stephen A. Harrison, MD, FACP, FAASLD (Radcliffe Department of Medicine, University of Oxford), and Steven K. Grinspoon, MD (Harvard Medical School), who will discuss the current treatment landscape and unmet medical need in treating patients with NASH, as well as discuss Theratechnologies’ Phase 3 development program evaluating tesamorelin for the treatment of NASH. Drs. Loomba, Harrison, and Grinspoon and Theratechnologies’ management team will be available to answer questions from the audience following the fireside chat.